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Acid ceramidase (ASAH1) a key enzyme of sphingolipid metabolism converting pro-
apoptotic ceramide to sphingosine has been shown to be overexpressed in various cancers.
We previously demonstrated higher expression of ASAH1 in ER positive compared to ER
negative breast cancer. In the current study we performed subtype specific analyses of
ASAH1 gene expression in invasive and non invasive breast cancer. We show that expres-
sion of ASAH1 is mainly associated with luminal A e like cancers which are known to have
the best prognosis of all breast cancer subtypes. Moreover tumors with high ASAH1 expres-
sion among the other subtypes are also characterized by an improved prognosis. The good
prognosis of tumors with high ASAH1 is independent of the type of adjuvant treatment in
breast cancer and is also detected in non small cell lung cancer patients. Moreover, even in
pre-invasive DCIS of the breast ASAH1 is associated with a luminal phenotype and a
reduced frequency of recurrences. Thus, high ASAH1 expression is generally associated
with an improved prognosis in invasive breast cancer independent of adjuvant treatment
and could also be valuable as prognostic factor for pre-invasive DCIS.
ª 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights
reserved.1. Introduction 2004) but on the other hand they act as bioactive effectorsSphingolipids represent a family of membrane lipids with
highly particular functions. On one hand they contribute
structurally to the cells membrane (Futerman and Hannun,etrics and Gynecology, G
de (T. Karn).
6
ochemical Societies. Publregulating a variety of cellular functions (Zheng et al., 2006).
Main players in sphingolipidmetabolism are ceramide, sphin-
gosine, and sphingosine-1-phosphate (Saddoughi et al., 2008;
Gangoiti et al., 2010). Ceramide is metabolized by acidoethe University Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt,
ished by Elsevier B.V. All rights reserved.
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further converted into sphingosine-1-phosphate through
sphingosine-kinases (SPHK) (Pyne and Pyne, 2010). While cer-
amide exhibit pro-apoptotic stimuli on cancer cells and
normal tissue (Morad and Cabot, 2013), the counterpart sphin-
gosine-1-phosphate functions as an anti-apoptotic signal
regulating proliferation, inflammation, angiogenesis and
resistance to apoptotic cell death (Mao and Obeid, 2008;
Ponnusamy et al., 2010). Therefore a concept termed sphingo-
lipid rheostat has been proposed (Spiegel and Milstien, 2003).
Following this concept the dynamic equilibrium between the
different sphingolipid metabolites and balanced regulation
of opposing signalling pathways is a crucial factor that deter-
mines the fate of cells (Ponnusamy et al., 2010; Ryland et al.,
2011). Exogenous ceramide analoga affect this system
in vitro and have therapeutic potential in various tumors
(Canals et al., 2011; Barth et al., 2011) comprising breast cancer
(Struckhoff et al., 2004; Flowers et al., 2012; Gouaze-Andersson
et al., 2011; Morad et al., 2012), prostate cancer (Holman et al.,
2008; Norris et al., 2006; Saad et al., 2007), colon cancer (Dahm
et al., 2008), head and neck cancer (Mehta et al., 2000; Elojeimy
et al., 2007), leukaemia (Furlong et al., 2008), or pancreatic can-
cer (Jiang et al., 2011; Morad et al., 2013b). ASAH1 has been
shown to be overexpressed in various cancer types (French
et al., 2006), including head and neck cancer(Mehta et al.,
2000), prostate cancer (Norris et al., 2006; Saad et al., 2007;
Liu et al., 2009; Morad et al., 2013a; Mahdy, Ayman E M et al.,
2009) and melanoma (Musumarra et al., 2003). Previously we
found for sphingosine-kinase-1 (SPHK1) higher expression in
ER negative breast cancer as well as a poor prognostic value
(Ruckh€aberle et al., 2008) but a predictive value for response
to neoadjuvant chemotherapy (Ruckh€aberle et al., 2013). In
contrast, higher ASAH1 expressionwas found to be associated
with ER positive breast cancer and an improved prognosis
(Ruckh€aberle et al., 2009a). Breast cancer is a heterogeneous
disease composed of at least four major subtypes which differ
by expression of estrogen (ER) and progesterone (PgR) recep-
tors, HER2, and proliferative status (Reis-Filho and Pusztai,
2011; Goldhirsch et al., 2011; Prat et al., 2011). Current whole
genome projects also suggest additional molecular stratifica-
tion (Curtis et al., 2012; Karn, 2013; Koboldt et al., 2012;
Banerji et al., 2012) and revealed that e.g. “basal-like” breast
cancer may be considered as a distinct disease more related
to ovarian cancer than to other breast cancer subtypes
(Koboldt et al., 2012). Therefore it is pivotal to perform gene
expression analyses separately by breast cancer subtype to
avoid rediscovering the well known differences between the
subtypes (Prat et al., 2011; Weigelt et al., 2011; Rody et al.,
2011; Karn et al., 2011, 2012; Hanker et al., 2013b).
In the current study we conducted subtype specific ana-
lyses of ASAH1 expression in invasive breast cancer and
ductal carcinoma in situ (DCIS) on mRNA level and immuno-
histochemistry. Our results demonstrate that expression of
ASAH1 is preferentially associated with luminal A e like can-
cers and an improved prognosis. This better prognosis was in-
dependent of the type of adjuvant treatment and was also
detected in a cohort of non small cell lung cancer patients.
High ASAH1 was also associated with luminal phenotype in
DCIS and could be associated with a reduced frequency of re-
currences in this early type of disease.2. Materials and methods
All analyses in this study were performed according to the
“REporting recommendations for tumour MARKer prognostic
studies” (REMARK) (McShane et al., 2005; Simon et al., 2009)
and the respective guidelines to microarray-based studies
for clinical outcomes (Dupuy and Simon, 2007).
2.1. Gene expression data
We used a previously described (Hanker et al., 2013b; S€anger
et al., 2014) cohort of compiled Affymetrix gene expression
data (U133A or U133Plus2.0 arrays) of 4467 breast cancer pa-
tients from 40 publicly available datasets (Supplementary
Table S1). Affymetrix CEL files were processed with the
MAS5.0 algorithm of the affy package (Gautier et al., 2004) of
the Bioconductor software project (Gentleman et al., 2004).
Data from each array were log2-transformed, median-
centered, and expression values of all the probesets from the
U133A array were multiplied by a scale factor S so that the
magnitude (sum of the squares of the values) equals one. The
bimodal distributions of ESR1, PgR, HER2, andOPG gene expres-
sion were used to derive cutoffs to differentiate high and low
expression, or positive and negative status, respectively, as
described previously (Karn et al., 2010). Two different methods
were applied to define molecular subtypes of breast cancer.
First, to approximate the intrinsic subtypes of breast cancer
we used the simple method according to Hugh et al. (Hugh
et al., 2009) which is based on the expression of single marker
genes (ESR1, PgR, HER2, Ki67) to define TNBC-, HER2-, Luminal
A-, and Luminal B-subtypes. For a distinction of Luminal A
and Luminal B subgroups all 2884 ERpositive/HER2negative
samples were selected and a median split according to Ki67
expressionwas performed. In addition all 106 ERpositive/HER2-
positive cases were also assigned to the Luminal B subtype ac-
cording to this method (Hugh et al., 2009). As a second,
alternativemethodfor subtypedetermination,weappliedasin-
gle sample predictor (SSP) (Weigelt et al., 2010) according to the
centroid method using the gene set from Hu et al. (2006). The
centroid analyseswere performed separately in six larger data-
sets encompassing a total of 1142 samples. Respective subtype
designations by both methods for each individual sample are
given in Supplementary Table S2. Several different probesets
for ASAH1were available on the Affymetrix U133Amicroarray.
We had previously shown that the highest consistency was
found for probesets 210980_s_at and 213702_x_at (Ruckh€aberle
et al., 2009a). Againwe verified this result in the current dataset
(Supplementary FigureS1) andusedprobeset 210980_s_at for all
subsequentanalysesofASAH1expression.Affymetrixmicroar-
ray data from ductal carcinoma in situ (DCIS) were obtained
from a dataset published by Vincent-Salomon et al. (Vincent-
Salomon et al., 2008) and were downloaded from caArray
(https://array.nci.nih.gov/caarray/project/vince-00013).
2.2. Statistical analysis
Chi-Square and Fisher’s Exact Test were used to determine sig-
nificance of categorical variables. KruskaleWallis Test and
ManneWhitney U-Test were used to analyze differences in
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formation was available for 2794 of the 4467 invasive breast
cancer samples. For 1463 samples the survival endpoint was
relapse free survival (RFS) including local recurrences, for
1331 samples only distant metastasis free survival (DMFS)
was available. In the conduct of the presented analysis event
free survival (EFS) was calculated as preferentially correspond-
ing to the RFS endpoint including local relapses, but measured
with respect to the DMFS endpoint if RFS was not available. All
results from survival analyses were verified by examining the
effect of different endpoints in stratified analyses. Follow up
data for those women in whom the envisaged end point was
not reached were censored as of the last follow-up date or at
120 months. Subjects with missing values were excluded
from the analyses. We constructed KaplaneMeier curves and
used the log-rank test to determine univariate significance of
the variables. A Cox proportional-hazards model was used to
simultaneously examine the effects of multiple covariates on
survival. The effect of each individual variable was assessed
with the use of theWald test and described by the hazard ratio,
with a 95 percent confidence interval (95% CI). All analyses
were performed using SPSS Statistics Version 22 (IBM Corp.)
and R 3.0.1 (www.r-project.org). In addition, the online KM
plotter database (Gy€orffy et al., 2010) (http://www.kmplot.com)
was also used for survival analysis in ER positive cohorts with
different types of adjuvant treatment (Mihaly et al., 2013).
2.3. Immunohistochemical analysis of ASAH1
expression
Tissue samples of 38 cases of pure DCIS were obtained from
routine pathological procedures with IRB approval and
informed consent. Histopathology sections stained with
hematoxylin-eosin were used for primary diagnosis and sec-
ond reviewing (K.E.). Aftermounting on Superfrost Plus slides,
paraffin sections (2 mm) were dewaxed in xylene and rehy-
drated to water through a graduated ethanol series. For anti-
gen retrieval, sections were incubated for 20 min in a
microwave oven (800 W) using EDTA buffer (10 mmol/L; pH
8.0). Sections were incubated with a monoclonal anti-ASAH1
antibody (Biozol Diagnostica, Germany; cat. no. H00000427-
M01, Clone2C9) at a 1:100 dilution for 1 h at room temperature.
For negative controls, the primary antibody (Ab) was omitted.
For secondary antibody incubation, the Dako REAL Detection
System Alkaline Phosphatase (Dako, Denmark) was applied,
following the instructions of the vendor. Sections were coun-
terstained with hematoxylin. Staining intensity was assigned
semiquantitatively as 0, negative; 1, weak; 2, moderate; or 3,
strong. The sample cohort were then dichotomized in low
(0,1) or high (2,3) ASAH1 expression. All assessments were
made blinded with respect to clinical patient data.3. Results
3.1. ASAH1 gene expression is associated with Luminal
A subtype of breast cancer
We analyzed Affymetrixmicroarray expression data of a com-
bined cohort of 4467 primary invasive breast cancer samplescompiled from 40 different datasets that we have described
recently (Hanker et al., 2013b; S€anger et al., 2014). Clinical Pa-
rameters of the patients are given in Table 1. We first
compared expression of ASAH1 gene among the different mo-
lecular subtypes of breast cancer. We used two alternative
strategies to determine the molecular subtypes as described
in detail in the Methods section: Either a single marker
method according to Hugh et al. (Hugh et al., 2009) or the
centroid method using the intrinsic gene set (Hu et al., 2006;
Weigelt et al., 2010). Results according to the single marker
method were available for all 4467 samples, the classification
according to the centroid method for 1142 samples. Figure 1
shows that expression of ASAH1 differed between subtypes
(P < 0.001, KruskaleWallis Test). High expression of ASAH1
was observed in the luminal subtypes of breast cancer, espe-
cially in Luminal A samples, independently of the applied sub-
typing methodology. Low ASAH1 expression was detected in
TNBC and basal-like cancer while samples from the HER2-
like subgroup displayed intermediate expression.3.2. High ASAH1 expression correlates with better
prognosis
We further studied the prognostic value of ASHA1 expression
in the tumor for relapse free survival of the patient. Follow up
data were available for 2794 of the 4467 samples. Figure 2A
shows the KaplaneMeier analysis of the 2794 patients strati-
fied according to quartiles of ASAH1 expression. An improved
survival was detected for patients within the highest quartile
of ASAH1 expression (P < 0.001). Table 1 also presents clinical
parameters of patients from the highest quartile of ASAH1
expression compared to those with low ASAH1 expression.
Patients with high ASAH1 are characterized by a higher pro-
portion of ER positive, PgR positive, and lymph node positive
patients while those with low ASAH1 encompass more grade
3 and HER2 positive tumors, and patients with young age.
The difference in survival in Figure 2A seem to reflect that
high expression of ASAH1 was observed in the luminal sub-
types of breast cancer (see Figure 1 above) which are known
to have a better prognosis than TNBC and HER2-like subtypes.
We therefore also repeated the KaplaneMeier analysis sepa-
rately for each breast cancer subtype in Figure 2BeE. A signif-
icant difference in prognosis was detected mainly within the
Luminal B subtype (P ¼ 0.004; Figure 2C) but not for Luminal
A tumors (P ¼ 0.14; Figure 2B). As shown in Figure 2D,E only
very few patients in the TNBC and HER2-like subgroups dis-
played strong ASAH1 expression (highest quartile). The better
survival of these only 9 and 10 patients, respectively, was not
statistically significant (P ¼ 0.10 and P ¼ 0.24; Figures 2D and
2E, respectively).
Table 2 presents the results of a multivariate Cox regres-
sion analysis of survival including ASAH1, the molecular sub-
type classification, and all clinical parameters in 870 patients
for which all parameters were available. In this analysis only
the molecular subtype of the tumor remained significant
while ASAH1 only showed a trend towards significance
(P¼ 0.090). In an additional analysis, inwhichwe replacedmo-
lecular subtype classification by ER, PgR, and HER2 receptor
status, only PgR status remained significant (P ¼ 0.005) while
Table 1 e Clinical characteristics of 4467 primary invasive breast cancer samples with Affymetrix microarray data from 40 datasets.
Parameter Total Low ASAH1 (n ¼ 3350) High ASAH1 (n ¼ 1117) P-value
Lymph node status LNN 2040 62.5% 1625 64.0% 415 57.1%
Nþ 1225 37.5% 913 36.0% 312 42.9% 0.001
Age Age > 50 1908 61.1% 1349 56.7% 559 75.0%
Age  50 1217 38.9% 1031 43.3% 186 25.0% 0.001
Tumor size 2 cm 358 20.3% 308 20.3% 50 20.6%
>2 cm 1403 79.7% 1210 79.7% 193 79.4% n.s.
Grade G3 1524 49.2% 1285 54.0% 239 33.2%
G1 & G2 1575 50.8% 1095 46.0% 480 66.8% <0.001
ER status Positive 2990 66.9% 2024 60.4% 966 86.5%
Negative 1477 33.1% 1326 39.6% 151 13.5% <0.001
PgR status Positive 2466 55.2% 1669 49.8% 797 71.4%
Negative 2001 44.8% 1681 50.2% 320 28.6% <0.001
HER2 status Positive 589 13.2% 518 15.5% 71 6.4%
Negative 3878 86.8% 2832 84.5% 1046 93.6% <0.001
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cance (P ¼ 0.063 for both; Supplementary Table S3).
We then looked within the luminal subtype for possible re-
lationships of different treatments and the prognostic value of
ASAH1 expression. For this purpose we applied an updated
version of the KM plotter database (Gy€orffy et al., 2010)
including adjuvant treatment information (Mihaly et al.,
2013). As demonstrated in Figure 3AeD the positive prognostic
effect of high ASAH1 expression was detected among all ER
positive patients, irrespective of whether they obtained endo-
crine treatment, cytotoxic chemotherapy, or no adjuvant ther-
apy. Interestingly, using a recently developed similar database
for lung cancer (GyTrffy et al., 2013) we also detected a strong
prognostic value of ASAH1 expression in non small cell lung
cancer (NSCLC) as shown in Figure 3EeF.
3.3. ASAH1 expression in luminal subtype of ductal
carcinoma in situ
We next studied microarray data from non invasive ductal
carcinoma in situ (DCIS). We intended to analyze whether
high AHSAH1 expression is already detectable and also asso-
ciated with a luminal subtype in this pre-invasive form ofA
Figure 1 e ASAH1 gene expression in different molecular subtypes of breas
microarray (probeset 210980_s_at) are shown for molecular subtypes of bre
classification was either performed using a single marker method according t
breast cancer samples from 40 datasets. In (B) the centroid method using the
1142 samples from six large datasets. Highest expression of ASAH1 was det
Values are given according to KruskaleWallis Test for difference in expresdisease. We used a published Affymetrix dataset encompass-
ing a total of 26 DCIS cases, 18 of which are luminal (ER pos-
itive) and 8 non luminal (HER2-positive/ER negative)
(Vincent-Salomon et al., 2008). ASAH1 expression clearly
differed between those two groups of DCIS with high expres-
sion in the luminal subtype (Figure 4A, P ¼ 0.030, Man-
neWhitney U Test). We then set out to verify this result on
the level of protein expression by using immuno-histo-
chemistry (IHC). We performed IHC of ASAH1 and ER on 38
cases of DCIS from our own institution. As shown in
Figure 4B we also detected by this method a trend for higher
ASAH1 expression in the ER positive luminal subtype of DCIS
(P ¼ 0.19). When analyzing the available follow up from this
dataset we observed less recurrences in the group of DCIS
with high ASAH1 expression by IHC but obtained no statisti-
cal significance in this small group of 21 patients (P ¼ 0.22,
Figure 4C).4. Discussion
In previous studies we reported increased expression of
ASAH1 in ER positive breast tumors and an improved survivalB
t cancer. Box plots of ASAH1 gene expression measured by Affymetrix
ast cancer defined by two alternative approaches. In (A) subtypes
o Hugh et al. (Hugh et al., 2009) among 4467 pre-therapeutic invasive
intrinsic gene set (Weigelt et al., 2010; Hu et al., 2006) was applied to
ected in the Luminal A subtype of breast cancer by both methods. P-
sion between subtypes.
A B
DC
E
Figure 2 e Prognostic value of ASAH1 expression in molecular subtypes of breast cancer. KaplaneMeier analysis of event free survival of breast
cancer patients according to quartiles of ASAH1 gene expression among all samples is given in panel A. Separate analysis for the different
molecular subtypes of breast cancer defined according to the single marker method are given in panels BeE. In each graph sample numbers and P-
values of log-rank test are provided for the comparison of the upper quartile (Q4) against the rest of the samples (Q1eQ3).
Table 2 eMultivariate Cox regression analysis of survival according
to ASAH1 expression and molecular subtypes and standard
parameters.
Parameter Numbersa HR 95% CI P-value
ASAH1 (High vs. Low) 107 vs. 763 0.71 0.47e1.06 0.090
Lymph node status
(LNN vs. Nþ)
662 vs. 208 0.81 0.61e1.08 0.15
Age (>50 vs. 50) 466 vs. 404 1.13 0.90e1.43 0.29
tumor size
(1 cm vs. >1 cm)
238 vs. 632 0.91 0.69e1.20 0.50
Histological grading
(G3 vs. G1&G2)
484 vs. 386 1.05 0.82e1.34 0.71
Molecular subtype: TNBC 261 <0.001
HER2 91 0.94 0.61e1.44 0.77
LumA 255 0.68 0.48e0.97 0.031
LumB 263 1.40 1.05e1.86 0.023
a Information on all six parameters was available for 870 of the
2590 samples with follow up data.
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sent study we have considerably enlarged sample size,
analyzed ASAH1 expression in different molecular subtypes
of breast cancer and have also extended our observations to
pre-invasive breast tumors of ductal carcinoma in situ. Beside
breast cancer acid ceramidase (ASAH1) has been reported to
be involved in several other types of cancer as prostate cancer
(Holman et al., 2008; Saad et al., 2007;Mahdy, Ayman EMet al.,
2009), leukaemia (Furlong et al., 2008), colon cancer (Selzner
et al., 2001), and head and neck cancer (Elojeimy et al., 2007).
But data on the prognostic value of differences in ASAH1
expression are relatively scarce. We previously detected
increased levels of different ceramids in human breast cancer
tissues compared to benign samples and found a positive as-
sociation with the ER status (Schiffmann et al., 2009). In
contrast, overexpression of ASAH1 has been shown to reduce
ceramide and increase S1P levels, which has been related to
the stimulation of cancer progression (Huwiler and
Figure 3 e Prognostic value of ASAH1 in luminal breast cancer according to treatment and NSCLC. The KM-plotter (Gy€orffy et al., 2010)
database was used to analyze the prognostic value of ASAH1 expression in different subsets of ER positive breast cancers according to adjuvant
treatment in panels AeD with either all ER positive BC patients (A), ER positive BC patients without any systemic therapy (B), and ER positive
BC patients with only endocrine treatment (B) or chemotherapy (C). In addition the prognostic effect of ASAH1 expression in non small cell lung
cancer (NSCLC) is shown for all patients (E) or those patients with negative surgical margin (F).
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correlation of higher ASAH1 expression with ER positive
breast cancer and with a better prognosis is rather counterin-
tuitive. However, sphingolipid metabolism pathways are
known to be highly complex and interconnected (Futerman
and Hannun, 2004; Zheng et al., 2006; Saddoughi et al., 2008;
Gangoiti et al., 2010; Morad and Cabot, 2013). In addition to
ASAH1 several other enzymes as e.g. ceramide synthasescan contribute to the cellular ceramide level and the expres-
sion of these enzymes also differed significantly between ER
positive and ER negative breast tumors (Ruckh€aberle et al.,
2008, 2009b, 2009c). Interestingly, we did also detect a better
prognosis for high ASAH1 gene expression in a cohort of non
small cell lung cancer patients in our present study
(Figure 3E,F). Moreover, immunohistochemical analyses of
epithelial ovarian cancer suggested that high ASAH1
A B C
Figure 4 e ASAH1 expression in ductal carcinoma in situ (DCIS) of the breast. A)ASAH1 gene expression in ductal carcinoma in situ (n[ 26) of
luminal (ER positive) or non-luminal (ER negative) type from a published microarray dataset (P [ 0.030; ManneWhitney U-Test). B)
Differences in ER-status in DCIS samples characterized for ASAH1 by immunohistochemistry (n [ 38; P [ 0.19, Fishers’s Exact Test). C)
KaplaneMeier analysis of disease free survival after DCIS characterized by ASAH1 immunohistochemistry (n[ 21; P[ 0.22, LogeRank Test).
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outcome (Hanker et al., 2013a). Our cohort of 39 DCIS patients
with both immunohistochemical data and followupmay have
been too small to detect a similar result with statistical signif-
icance (P¼ 0.22; Figure 4C). Still, all these results seem to asso-
ciate a higher ASAH1 expression with improved patient
prognosis in different types of cancer. In vitro studies demon-
strate that ASAH1 expression can be induced by radiation and
ASAH1 overexpression increased chemotherapy resistance of
cancer cells (Saad et al., 2007; Mahdy, Ayman E M et al., 2009).
On the other hand tamoxifen downregulates ASAH1 protein in
different cancer cell types (Morad et al., 2013a). Detailed data
on radiotherapywas not available for our patient cohort. How-
ever, we observed the positive prognostic value of ASAH1
expression independent of the type of adjuvant treatment
that breast cancer patients had received (chemotherapy,
endocrine therapy, or no adjuvant treatment; Figure 3B,C,D).
Nevertheless, this observation may not argue against e.g. an
influence of ASAH1 on chemotherapy resistance since it could
have both a prognostic and a predictive role as we e.g. have
previously shown for SPHK1 (Ruckh€aberle et al., 2008, 2013).
We detected a correlation of ASAH1 expression with a luminal
ER positive differentiation already among pre-invasive forms
of ductual carcinoma in situ of the breast (Figure 4A,B).
Clearly, much larger cohorts are needed to verify a potential
association of high ASAH1 and a reduced frequency of recur-
rences in this early type of disease. But since current prog-
nostic factors for DCIS are often unsatisfactory this result
could be of clinical interest. A strength of our study is a large
sample size but limitations include the retrospective design
of the analysis and the availability of only mRNA expression
data for most of the samples. Thus our study could miss po-
tential regulation of protein expression and has no data on
the actual level of different sphingolipids in the biological
samples. All samples were pretherapeutic biopsies, so
possible influences of treatment on ASAH1 expression could
not be observed.
In conclusion we demonstrate that ASAH1 is preferen-
tially associated with low risk luminal A breast cancer. High
ASAH1 expression is overall associated with an improved
prognosis in invasive breast cancer independent of adjuvant
treatment and may also be a prognostic factor for pre-
invasive DCIS.Funding
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